Knocking down miR-384 promotes growth and metastasis of osteosarcoma MG63 cells by targeting SLBP

References

• Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004. Cancer. 2009;115:1531–1543.
   PubMed Web of Science ®Google Scholar
• Price CH. Osteogenic sarcoma: an analysis of the age and sex incidence. Br J Cancer. 1955;9:558–574.
   PubMed Web of Science ®Google Scholar
• Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report. Clin Orthopaed Relat Res. 2007;459:40–47.
   PubMed Web of Science ®Google Scholar
• Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. In: Jaffe N, Bruland OS, Bielack S, editors. Pediatric and adolescent osteosarcoma. Boston, MA: Springer US; 2010. p. 3–13.
   Google Scholar
• Thompson LD. Osteosarcoma. Ear Nose Throat J. 2013; 92:288, 290.
   PubMed Web of Science ®Google Scholar
• Jiang R, Zhang C, Liu G, et al. MicroRNA-101 inhibits proliferation, migration and invasion in osteosarcoma cells by targeting ROCK1. Am J Cancer Res. 2017;7:88–97.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang Y, Yang T, et al. Long non-coding RNA MALAT1 for promoting metastasis and proliferation by acting as a ceRNA of miR-144-3p in osteosarcoma cells. Oncotarget. 2017;8:59417–59434.
   PubMedGoogle Scholar
• Fontana L, Pelosi E, Greco P, et al. MicroRNAs 17-5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation. Nat Cell Biol. 2007;9:775–787.
   PubMed Web of Science ®Google Scholar
• Valencia-Sanchez MA, Liu J, Hannon GJ, et al. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20:515. 24.
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs – microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–269.
   PubMed Web of Science ®Google Scholar
• Osaki M, Takeshita F, Sugimoto Y, et al. MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther. 2011;19:1123–1130.
   PubMed Web of Science ®Google Scholar
• Duan Z, Choy E, Harmon D, et al. MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration. Mol Cancer Ther. 2011;10:1337–1345.
   PubMed Web of Science ®Google Scholar
• Ziyan W, Shuhua Y, Xiufang W, et al. MicroRNA-21 is involved in osteosarcoma cell invasion and migration. Med Oncol. 2011;28:1469–1474.
   PubMed Web of Science ®Google Scholar
• Zhao G, Cai C, Yang T, et al. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One. 2013;8:e53906.
   PubMed Web of Science ®Google Scholar
• Song H, Rao Y, Zhang G, et al. MicroRNA-384 inhibits the growth and invasion of renal cell carcinoma cells by targeting astrocyte elevated gene 1. Oncol Res. 2018;28:457–466.
   Web of Science ®Google Scholar
• Fan N, Zhang J, Cheng C, et al. MicroRNA-384 represses the growth and invasion of non-small-cell lung cancer by targeting astrocyte elevated gene-1/Wnt signaling. Biomed Pharmacother. 2017;95:1331–1337.
   PubMed Web of Science ®Google Scholar
• Wang YX, Chen YR, Liu SS, et al. MiR-384 inhibits human colorectal cancer metastasis by targeting KRAS and CDC42. Oncotarget. 2016;7:84826–84838.
   PubMedGoogle Scholar
• Lai YY, Shen F, Cai WS, et al. MiR-384 regulated IRS1 expression and suppressed cell proliferation of human hepatocellular carcinoma. Tumor Biol. 2016;37:14165–14171.
   PubMedGoogle Scholar
• Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma: where do we go from here? Paediatr Drugs. 2008;10:315–327.
   PubMedGoogle Scholar
• Miao J, Wu S, Peng Z, et al. MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects. Tumor Biol. 2013;34:2093–2098.
   PubMed Web of Science ®Google Scholar
• Chen Z, Yu C, Zhan L, et al. LncRNA CRNDE promotes hepatic carcinoma cell proliferation, migration and invasion by suppressing miR-384. Am J Cancer Res. 2016;6:2299–2309.
   PubMed Web of Science ®Google Scholar
• Zhang B, Pan X, Cobb GP, et al. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302:1–12.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–233.
   PubMed Web of Science ®Google Scholar
• Marzluff WF, Wagner EJ, Duronio RJ. Metabolism and regulation of canonical histone mRNAs: life without a poly(A) tail. Nat Rev Genet. 2008;9:843–854.
   PubMed Web of Science ®Google Scholar
• Whitfield ML, Zheng LX, Baldwin A, et al. Stem-loop binding protein, the protein that binds the 3' end of histone mRNA, is cell cycle regulated by both translational and posttranslational mechanisms. Mol Cell Biol. 2000;20:4188–4198.
   PubMed Web of Science ®Google Scholar
• Black D, Bird MA, Hayden M, et al. TNF alpha-induced hepatocyte apoptosis is associated with alterations of the cell cycle and decreased stem loop binding protein. Surgery. 2004;135:619–628.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Ramirez I, Soto-Reyes E, Sanchez PY, et al. Histones and long non-coding RNAs: the new insights of epigenetic deregulation involved in oral cancer. Oral Oncol. 2014;50:691–695.
   PubMed Web of Science ®Google Scholar
• Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005;435:1262–1266.
   PubMed Web of Science ®Google Scholar
• Seligson DB, Horvath S, McBrian MA, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol. 2009;174:1619–1628.
   PubMed Web of Science ®Google Scholar
• Monteiro FL, Baptista T, Amado F, et al. Expression and functionality of histone H2A variants in cancer. Oncotarget. 2014;5:3428–3443.
   PubMedGoogle Scholar
• Han G, Wang Y, Bi W. C-Myc overexpression promotes osteosarcoma cell invasion via activation of MEK-ERK pathway. Oncol Res. 2012;20:149–156.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yu X-H, Yan Y-G, et al. PI3K/Akt signaling in osteosarcoma. Clin Chim Acta. 2015;444:182–192.
   PubMed Web of Science ®Google Scholar
• Hou C-H, Lin F-L, Hou S-M, et al. Cyr61 promotes epithelial-mesenchymal transition and tumor metastasis of osteosarcoma by Raf-1/MEK/ERK/Elk-1/TWIST-1 signaling pathway. Mol Cancer. 2014;13:236.
   PubMed Web of Science ®Google Scholar
• Yu Y, Luk F, Yang JL, et al. Ras/Raf/MEK/ERK pathway is associated with lung metastasis of osteosarcoma in an orthotopic mouse model. Anticancer Res. 2011;31:1147–1152.
   PubMed Web of Science ®Google Scholar
• Jin S, Pang R-P, Shen J-N, et al. Grifolin induces apoptosis via inhibition of PI3K/AKT signalling pathway in human osteosarcoma cells. Apoptosis. 2007;12:1317–1326.
   PubMed Web of Science ®Google Scholar
• Li B, Yang Y, Jiang S, et al. Adenovirus-mediated overexpression of BMP-9 inhibits human osteosarcoma cell growth and migration through downregulation of the PI3K/AKT pathway. Int J Oncol. 2012;41:1809–1819.
   PubMed Web of Science ®Google Scholar
• Liu B, Shi Z-l, Feng J, et al. Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt. Cell Biol Int. 2008;32:494–501.
   PubMed Web of Science ®Google Scholar